Al Mayadeen English

  • Ar
  • Es
  • x
Al Mayadeen English

Slogan

  • News
    • Politics
    • Economy
    • Sports
    • Arts&Culture
    • Health
    • Miscellaneous
    • Technology
    • Environment
  • Articles
    • Opinion
    • Analysis
    • Blog
    • Features
  • Videos
    • NewsFeed
    • Video Features
    • Explainers
    • TV
    • Digital Series
  • Infographs
  • In Pictures
  • • LIVE
News
  • Politics
  • Economy
  • Sports
  • Arts&Culture
  • Health
  • Miscellaneous
  • Technology
  • Environment
Articles
  • Opinion
  • Analysis
  • Blog
  • Features
Videos
  • NewsFeed
  • Video Features
  • Explainers
  • TV
  • Digital Series
Infographs
In Pictures
  • Africa
  • Asia
  • Asia-Pacific
  • Europe
  • Latin America
  • MENA
  • Palestine
  • US & Canada
BREAKING
An Iranian missile hit an Israeli governmental compound in Haifa.
Talks begin in Geneva between Iranian Foreign Minister Abbas Araghchi and the E3.
Al Mayadeen correspondent: The E3 will present Araghchi with a four-point European plan that includes a complete end to uranium enrichment in Iran.
Iranian Foreign Minister Abbas Araghchi arrives at the venue of the negotiations that will soon begin with the E3.
Araghchi: The Israeli attacks on nuclear facilities in Iran are serious war crimes.
Araghchi: We are determined to defend our territorial integrity and sovereignty with full force.
Araghchi: We were supposed to meet with the Americans on June 15 to draft a highly promising agreement regarding our nuclear program.
Araghchi: The unjustified Israeli attack on Iran is a violation of International Humanitarian Law Article 33.
Araghchi: Iran is facing aggression that cannot be justified in any way, and justifying this aggression is an act of complicity.
Araghchi: "Israel" bombed nuclear facilities that are under the supervision of the International Atomic Energy Agency (IAEA).

Weight-loss drug cuts risk of heart attack, strokes: Novo Nordisk

  • By Al Mayadeen English
  • Source: Agencies
  • 9 Aug 2023 11:10
3 Min Read

This preliminary study implies that this class of weight-loss drugs can impart long-lasting improvements to cardiovascular health.

  • x
  • Photo of the former North American headquarters of Novo Nordisk, Inc., in Plainsboro, N.J. taken on April 24, 2008. (AP)
    Photo of the former North American headquarters of Novo Nordisk, Inc., in Plainsboro, N.J. taken on April 24, 2008. (AP)

In a statement released on Tuesday that sent the firm's shares leaping to a record high, Danish pharmaceutical giant Novo Nordisk claimed that the obesity medicine Wegovy reduces the risk of heart attacks and strokes by a fifth.

Even though it is preliminary, this is the first study to imply that this class of weight-loss drugs, which has garnered substantial public interest, can impart long-lasting improvements to cardiovascular health.

17,604 overweight or obese adults aged 45 participated in the research, and they were randomly assigned to receive either the injectable medication or a placebo over the course of five years.

Strokes, heart attacks, and cardiovascular deaths all decreased by 20%, according to a statement from Novo Nordisk, though the company did not provide a breakdown for each category.

Read: Mediterranean diet can reduce heart attacks, study finds

It added that it planned to file for regulatory approval to broaden the usage for Wegovy in the US and the EU in 2023. The trial's comprehensive results will be published at a scientific meeting later this year.

Related News

Study finds Ozempic good for the heart, not just weight loss

BMI metric has caused 'historical harm': AMA

On Tuesday, Novo Nordisk's stock price increased by more than 17% at market closing in Copenhagen.

"We are very excited about the results," Martin Holst Lange, the company's executive vice president for development said, adding that the drug "has the potential to change how obesity is regarded and treated".

The results were also welcomed by the medical community.

Even though the trials "still need to be confirmed through careful peer review," they still show "the urgent need for patients living with obesity to be offered this effective and safe drug to prevent future disease," according to Simon Cork, senior lecturer in physiology at Anglia Ruskin University, who did not participate in the research.

According to Naveed Sattar, a professor of metabolic medicine, the University of Glasgow, the results "are exciting as preventing heart attacks and stroke with a drug that also lowers weight is very important for many patients." He also did not take part in the research but has previously consulted for Novo Nordisk.

Wegovy and the diabetes medication Ozempic are both produced by Novo Nordisk, the largest producer of insulin in the world. In May, the company reported a 39 percent increase in first-quarter earnings, helped by sales of its obesity therapies.

The European Medicines Agency, which has its headquarters in Amsterdam, announced in mid-July that it was examining data "on the risk of suicidal thoughts and thoughts of self-harm" with respect to three well-known weight-loss medications: Saxenda, Wegovy, and Ozempic. The last two both contain the active ingredient semaglutide.

Among more than a billion people worldwide suffering from obesity, according to the World Health Organization, there is intense competition among pharmaceutical companies to develop effective therapies.

  • overweight
  • stroke patients
  • Denmark
  • heart failure
  • obesity
  • Novo Nordisk

Most Read

Iranian missiles impact Israeli sites in Tel Aviv in 2nd wave

Iran's missiles impact 'strategic' Israeli site in Tel Aviv

  • Politics
  • 14 Jun 2025
Bin Salman: Islamic world backs Iran in call to Pezeshkian

MBS says Islamic world backs Iran in call with Pezeshkian

  • MENA
  • 15 Jun 2025
Iran launches 9th wave of Op. True Promise 3, destroys IOF air defense

Iran launches 9th wave of Op. True Promise 3, destroys IOF air defense

  • MENA
  • 17 Jun 2025
Smoke rises after an Iranian ballistic missile directly struck Tel Aviv, Occupied Palestine, June 13, 2025 (AP)

Op. True Promise 3: Iran's ballistic missiles strike Tel Aviv

  • MENA
  • 13 Jun 2025

Coverage

All
The Ummah's Martyrs

Read Next

All
Netanyahu stuns by postponing son’s wedding over Iran war
Politics

Netanyahu sparks outrage citing son’s wedding delay as Iran war cost

French court postpones verdict to July 17 on Georges Abdallah
Europe

French court postpones verdict on Georges Abdallah to July 17

Perseverance to shorten war: Iran's Larijani
Politics

Larijani says Iran to hold IAEA chief accountable after war ends

Damage to the Weizmann Institute of Science from an Iranian missile strike in Rehovot, Thursday, June 19, 2025. (AP Photo/Maya Alleruzzo)
Politics

'Catastrophic loss': Iranian blow to Weizmann’s war-linked facilities

Al Mayadeen English

Al Mayadeen is an Arab Independent Media Satellite Channel.

All Rights Reserved

  • x
  • Privacy Policy
  • About Us
  • Contact Us
  • Authors
Android
iOS